Update on RNAi Technology Published By Genetic Engineering News (GEN)
Posted on: Friday, 4 November 2005, 09:00 CST
Genetic Engineering News (GEN) has published today a special supplement on RNAi, the revolutionary gene silencing technology that is having an enormous impact on biotechnology product development. Bioindustry analysts predict that RNAi will be a $1 billion market within five years. RNAi is the first supplement in a new series entitled GEN UPDATES in Biotechnology.
"RNAi technology is already being used in gene function analysis, systems biology, high content cellular studies, pathway analysis, and target validation," says John Sterling, Editor-in-Chief of GEN. "Researchers are discussing and investigating RNAi as a way to one day treat cancer, neurodegenerative diseases, AIDS, hepatitis C, and age-related macular degeneration."
The RNAi UPDATE (www.genengnews.com/rnai) articles include "Are siRNAs Specific Enough to Become Therapeutics; Interfering with RNA: Ready for Prime Time; Design Rules for Dicer-Substrate RNAi; Inducible H1 Promoter-Driven Lentiviral siRNA Expression by Stuffer Reporter Deletion; Gel-Based Application of siRNA to Human Epithelial Cancer Cells Induces RNAi-Dependent Apoptosis; and The Nonviral Episomal Replicating Vector pEPI-1 Allows Long-Term Inhibition of bcr-abl Expression by shRNA".
"Our UPDATES in Biotechnology series of supplements add significantly to the expanding knowledge base of critical life science news and information provided by GEN (www.genengnews.com) and peer reviewed journals published by Mary Ann Liebert, Inc. (www.liebertpub.com)," notes Sterling. "We have a 25-year history as the leading publisher in the field of biotechnology, and our knowledge of the technologies and their market values is unparalleled."
Genetic Engineering News is published 21 times a year by Mary Ann Liebert, Inc. For a copy of the issue, which includes the RNAi UPDATE, please call 914-740-2122, or email: ebicovny@liebertpub.com
Source: Business Wire
Related Articles
- Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
- New Gene Silencing Platform
- Silence Obtains Important Patent Protection for Lead Internal Development Compound, Atu027
- FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics' Unique Proprietary Chemistry
- Nature Biotechnology Publishes First Paper Describing NanoString's Technology
- Healthnostics Provides Update on Current Status and Forward Momentum
- The Position of Monoclonal Antibodies on the Market is Solidly Poised for Growth With Six Novel Therapies Expected to Launch Within the Next Five Years
- Analysis: Stem Cells As Diabetes Therapy
- Generex Biotechnology Publishes Studies Demonstrating Anti-Tumor Potential of Immunotherapeutic Vaccine
 |
 |
User Comments (0)
RSS Feeds